DARA BioSciences, Inc., a specialty pharmaceutical company, has entered
into an exclusive US agreement with Candiac based Uman Pharma Inc. for
commercial rights to gemcitabine, DARA's second newly licensed
anticancer agent.
In 2010, gemcitabine generated branded (GEMZAR-Eli Lilly) sales of $780 million, according to IMS data. It went off patent in 2011 in the US, and a year earlier in Europe. The drug is widely prescribed as first-line therapy for ovarian, breast, lung, and pancreatic cancers.
In 2010, gemcitabine generated branded (GEMZAR-Eli Lilly) sales of $780 million, according to IMS data. It went off patent in 2011 in the US, and a year earlier in Europe. The drug is widely prescribed as first-line therapy for ovarian, breast, lung, and pancreatic cancers.
Last month, DARA acquired exclusive US rights to market Soltamox (licensed from Rosemont Pharmaceuticals Ltd.), the only oral liquid formulation of tamoxifen for breast cancer patients who have difficulty swallowing tablet formulations or simply prefer a liquid form of the widely prescribed hormone blocking therapy.
DARA and Uman are working to identify future partnership opportunities for additional sterile injectable products in the oncology market.
No comments:
Post a Comment